Dyno Therapeutics has formed a new research partnership with Roche, focusing on the development of next-generation adeno-associated virus (AAV) gene therapy vectors for neurological diseases.
It is the second collaboration between the two companies, building on their initial agreement announced in October 2020, which also included liver-directed therapies.
Go deeper with GlobalData
Dyno will leverage its platform and sequence design technologies to design and discover new AAV capsids with enhanced functional properties.
Roche will handle the validation of the capsids and oversee their preclinical and clinical development, along with the commercialisation of multiple neurological gene therapy products.
Capsids are essential for in vivo gene delivery, aiming to address the limitations of current gene therapy vectors.
Dyno will receive an upfront payment of $50m from Roche, along with additional payments during the research phase, and clinical, potential preclinical and sales milestone payments that could exceed $1bn, along with royalties on commercial product net sales.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataDyno founder and CEO Eric Kelsic stated: “This new collaboration with Roche, focused on developing next-generation gene therapies for underserved patients with life-altering neurological diseases, is a testament to the outstanding progress made by Dyno’s platform and to the commitment we make to partners in all of our projects.
“Dyno’s platform brings the entire field closer to realising a future where all gene therapies are safe, effective and widely accessible to all patients who need them.”
Existing gene therapies have relied on a limited number of naturally occurring AAV vectors, which have been hindered by low delivery competence, pre-existing immunity challenges and manufacturability issues.
Dyno aims to tackle these hurdles by employing its low-shot efficient accelerated performance technology, which utilises AI and high-throughput in vivo data collection.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
